BioNTech Finalizes Acquisition of InstaDeep for $549M
AI, ML-based deal builds on the parties’ existing relationship.
BioNTech has officially completed the acquisition of InstaDeep Ltd.—a technology company in the artificial intelligence (AI) and machine learning (ML) space—for approximately $549 million. Although this deal was originally announced this past January, the news actually follows a history of collaboration between the two parties since 2019; it is important to note that BioNTech also provided an initial equity investment as part of InstaDeep’s Series B financing round in January 2022.
The acquisition supports BioNTech’s strategy of aiming to build capabilities in AI-driven drug discovery and development of immunotherapies and vaccines to address diseases with high unmet medical need. InstaDeep will operate as a UK-based global subsidiary of BioNTech.
In addition to BioNTech-focused projects, InstaDeep will continue to provide its services to clients in other industries, including in the technology and transport & logistics sectors. The transaction adds approximately 290 highly skilled professionals to BioNTech’s workforce, including teams in AI, ML, bioengineering, data science, and software development.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.
